Medical Developments International (MVP.AX) Azione Prezzo

Medical Developments International Ltd primarily operates in the healthcare industry.

The main competitors of Medical Developments International Ltd in the market include companies such as Pfizer, Johnson & Johnson, and GlaxoSmithKline.

Medical Developments International Ltd is a leading Australian pharmaceutical company specializing in the development and distribution of innovative medical devices and drugs. Founded in 1971, Medical Developments International Ltd has consistently demonstrated a commitment to improving patient outcomes through advanced healthcare products. With a strong focus on research and development, the company has successfully introduced breakthrough solutions in the areas of pain management, respiratory care, and emergency medicine. Over the years, Medical Developments International Ltd has garnered a solid reputation for delivering high-quality and effective medical solutions to healthcare professionals worldwide.

Medical Developments International Ltd has achieved significant milestones since its inception. The company has successfully developed and commercialized innovative medical solutions, positioning itself as a global leader in emergency medical products. Notably, Medical Developments International Ltd has received regulatory approvals for their flagship product, Penthrox, across various countries, including the EU, UK, Australia, New Zealand, and Canada. The company has also forged partnerships with renowned distributors, enabling them to expand their market presence and increase sales. Additionally, Medical Developments International Ltd has continuously invested in research and development to enhance their product portfolio, ensuring they remain at the forefront of medical advancements.

Medical Developments International Ltd (MDI) is primarily present in several countries and regions. The company has a global footprint with significant operations in Australia, New Zealand, and the United States. As an internationally recognized healthcare company, MDI caters to a wide range of markets worldwide, including Europe, Asia, and the Middle East. With its innovative medical solutions and strong market presence, Medical Developments International Ltd continues to expand its reach to meet the growing demand for its products and services across various countries and regions.

Medical Developments International Ltd represents the values of innovation, patient care, and commitment to excellence. With a corporate philosophy centered around improving health outcomes, they strive to develop and provide high-quality medical solutions. By continually researching and investing in cutting-edge technology, Medical Developments International Ltd aims to revolutionize healthcare and create effective treatments for various conditions. Their commitment to integrity, accountability, and ethical practices makes them a trusted leader in the industry. With a focus on improving the well-being of patients, Medical Developments International Ltd is dedicated to delivering innovative solutions that enhance the quality of life for individuals worldwide.

Gli analisti fissano attualmente un prezzo obiettivo medio di 0,86 AUD per l’azione Medical Developments International (mediana: 0,86 AUD), pari a +119,7 % rispetto all’ultimo prezzo. Il consenso si basa su 5 giudizi di analisti.

Medical Developments International Prezzi Obiettivo Analisti 2026

5 analisti valutano attualmente l’azione Medical Developments International: 4 raccomandano l’acquisto, 1 la tenuta e 0 la vendita.

Medical Developments International Prezzi Obiettivo Analisti 2026

Convertita al tasso di cambio attuale, l’azione Medical Developments International quota 0,24 EUR (0,39 AUD).

L’azione Medical Developments International (MVP.AX) è quotata su 2 borse, tra cui: ASX (MVP.AX).

Medical Developments International Ltd is an Australian company that offers sustainable solutions in the field of lifesaving, pain relief, and inhalation therapy. The company develops, manufactures, and distributes inhalers, pain relief products, and medical devices. In the lifesaving sector, the company offers the emergency inhalator system Penthrox. This system is used in the treatment of acute pain and injuries such as bone fractures and burns. The Penthrox system is easy to handle and can be quickly deployed by paramedics and emergency physicians on site. This technology is ideal for the military, sports events, and other public gatherings. The company also offers a wide range of pain relief products. The pain reliever Green whistle is a sustainable, hydrogen-based analgesic used in pain therapy. It is easy to use, safe, and effective. The device is ideal for use in hospitals, pain therapy, and palliative care. Inhalation therapy is the company's third business area. The company offers a wide range of inhalation devices specifically developed for people with asthma or other respiratory diseases. With the nebulizer "Nebu-Tech," patients receive precise dosage of the medication, which effectively reaches the lungs. The company has also developed solutions for kindergarten and school medicine to improve the treatment of children and students with asthma. Medical Developments International Ltd places special emphasis on sustainability and environmental friendliness. The company invests in research and development of sustainable technologies and materials to provide eco-friendly products and services. The products are designed for long-term use and can be easily recycled. The well-being of the patient is also a priority in production. No animal components are used, and high standards of quality and safety are ensured. In summary, Medical Developments International Ltd offers a wide range of products that can be used to save lives, alleviate pain, and treat respiratory diseases. The company is focused on sustainability and environmental friendliness and places special emphasis on quality and safety. With the marketing of high-quality products, the company aims to improve the lives of its customers.

Il fatturato di Medical Developments International ammonta a 42,57 Mio. AUD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il profitto di Medical Developments International ammonta a 626.000,00 AUD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Medical Developments International è attualmente 72,22. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Medical Developments International.

Il rapporto prezzo/fatturato (P/S) di Medical Developments International è attualmente 1,06. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Medical Developments International.

Il Quality Score AlleAktien per Medical Developments International è 5/10.

L'ISIN di Medical Developments International è AU000000MVP2. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Medical Developments International è A0BLXB. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Medical Developments International è MVP.AX. Con questo simbolo di borsa vengono negoziate le azioni Medical Developments International in borsa.